

## Responses to questions from Corporate Scrutiny responses (Companies 28<sup>th</sup> Sept 2023)

### Medtech Accelerator Ltd

1. The original decision for Medtech Accelerator Investment was taken by Cabinet in October 2017 (FP/912/08/17). A copy of the decision is shown below.



Medtech Accelerator  
decision Oct 2017.pdf

2. During the Committee discussion, reference was made to Medtech in relation to Anglia Ruskin University (ARU) and Harlow. This is unrelated to the investment in Medtech Accelerator Ltd, and instead relates to the development of a Medtech Innovation Centre in Harlow, where ECC provided a grant of £2.5m towards the acquisition of land, build and fit out of the centre. A copy of the decisions are shown below.



Medtech Innovation Centre Decision 2015. Medtech Innovation  
Centre decision 2017.

3. None of the investments made by Medtech Accelerator Limited have been made for technology or businesses located within Essex (the investments have been concentrated in Cambridge).
4. The 2021/22 accounts for Medtech were signed on 21 March 2023. These are available on Companies House.
5. To date there has been no income generated and the last income forecast suggested no substantial income until 2027.
6. Below is the detail of the 14 projects:

#### Completed projects

- **Endoluminal vacuum therapy device** - licensed for commercialisation, with regulatory approval now expected in 2025.
- **Cancer tissue ablation technology** – funding being sought to complete first in person clinical trial and CE submission is expected by the end of 2024.
- **Dissection Plane Splayer for soft tissue retraction** – patent being progressed, and additional funding opportunities are being pursued.
- **Neutrocheck** – on track to start clinical trials in 2023.
- **Safer Injection for Regional Anaesthesia (SAFIRA) device** – on the market in the US and EU.
- **Smart Mesh (heat activated polymerisation system)** – patent application passed first stage; full application likely to be submitted by March 2023.

### Completed projects

- **Arterial GlucoSave** – development and regulatory approvals are being accelerated prior to market launch (estimated for 2023)
- **Non-contact sleep apnoea diagnostic device** – small scale pilots planned to start with Papworth Hospital next year.
- **Novel Patch for Sampling Cervical Disease** – research and development has progressed well. Currently preparing application for grant funding.

### Ongoing projects

- **TumourVue: Precise intraoperative tumour localisation** – founders are currently looking for potential sources of funding to enable them to continue the project.
- **Real Time Available Resource Locator for emergency Patient Transfers (LocANTS)** – trial is going well and now looking to expand the trial to paediatrics.
- **Corneal Graft Suturing Ring** – user trials are expected to start with surgeons soon.

### Closed projects (failed)

- **Bone conduction technology to help children with ‘glue ear’** (£125,000 invested) - inventor is now progressing project via another route
- **New biologic coating to reduce implant related infections** (£84,000 invested) - proof of concept inconclusive and inventor is not pursuing project further.

### ECL (Essex Cares Ltd)

1. In 21/22, ECL had a turnover of £53.7m, of which 87% relates to ECC business.
2. In terms of ECC investment in ECL, there has been no investment in ECL other than ECC pay for services that ECL provided through contracts. There were implementation costs of the Local Authority Trading Company of circa £750,000.
3. ECC receive a dividend from ECL. To date, £3.4m of dividends have been paid over the last 4 years, with £1.9m expected for 2022/23 and 2023/24.

### Essex Housing LLP

1. To date, Essex Housing LLP have made 23 private sales since inception in February 2021. Schemes started before that date or schemes which involve

retained ECC land (eg redevelopment of libraries) are not undertaken via the LLP..

2. The income from sales receipts is used to fund the general operations of Essex Housing LLP and has not been allocated to specific schemes/projects.
3. The operation of Essex Housing is overseen by the Essex Housing Board. It is responsible for:
  - Owning the Essex Housing Business Plan
  - Approving investment decisions below £2m
  - Recommending investment decisions to ECC above £2m
  - Performance management/monitoring
  - Overseeing the operation of the LLP
  - Reporting to the Shareholder Leads and Cabinet Member
4. The Board meets circa monthly alongside a programme of informal Board Development sessions.
5. The current Essex Housing LLP Board Members are:
  - Chairman (and casting vote) – Cllr Ray Gooding
  - Director – Stephanie Mitchener, Director of Finance, ECC
  - Director – Chris Martin, Director of Strategic Commissioning and Policy, ECC
  - Managing Director – Gwyn Owen, Managing Director, Essex Housing
  - Independent Board Member (appointed by the Board) - Alan Lewin

### **Remuneration of ECC Company Directors**

1. The payment of ECC Company Directors is set out in 4.3 to 4.6 of the Company guidance.
2. ECC officers are not paid any additional remuneration in addition to the salary paid by ECC. Exceptions can be approved by the Section 151 officer. This is on a case-by-case basis.
3. To date, there has only been 1 exception approved, relating to Peter Fairley, Director of Strategy, Policy & Integration. Peter took on an additional role of Interim Managing Director of ECL. This additional remuneration was also approved by Senior Management Employment Committee.